chuv.ch Background and objectives: Recombinant human growth hormone (rhGH) has been on the list of forbidden substances since availability of its recombinant form improved in the early 1990s. Although ...

Following the success of Humulin, recombinant DNA technology was quickly adopted to replace older methods of producing medical products from human growth hormone to vaccines. Although scientists have ...

Only one bone-forming agent, PTH 1–34 (which comprises the first 34 residues of recombinant human parathyroid hormone [PTH]), is currently available for clinical use. PTH-related protein (PTHrP ...

Given the early promise of transcriptomics, research using an ‘omics’-based approach involving genomics, transcriptomics, proteomics and metabolomics should be intensified in order to achieve improved ...

About Growject ® Growject ® is an injectable preparation containing recombinant human growth hormone, first launched in Japan by JCR in 1995. The dosage is administered subcutaneously 6–7 ...